Monlunabant dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Monlunabant is Novo Nordisk's CB1 blocker pill, built to act mostly outside the brain. People lost 7.1 kg in 16 weeks, but anxiety, irritability and sleep problems rose with the dose. A follow-up study has to sort that out.
Evidence grade for Monlunabant: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Monlunabant is a daily pill from Novo Nordisk. It blocks the CB1 receptor, the one cannabis acts on. It is meant to work mostly outside the brain. It is not approved.
What people take it for
- Weight loss from a pill.
- Kidney disease from diabetes.
What studies in people showed
The main study had 243 adults and ran 16 weeks. On 10 mg, people lost 7.1 kg. People on a dummy pill lost 0.7 kg. But anxiety, irritability and sleep problems rose as the dose went up. An older drug that worked the same way, rimonabant, was pulled from the market for that reason. A follow-up study is looking for a safe dose. It has not reported.
What people report
Reports, not study results
The good
- In the study on this page, people lost about 7 kg in 16 weeks.
The bad
- Anxiety, irritability and sleep problems rose with the dose in the study on this page.
Where these come from: Both lines are from the study on this page. We have not collected forum or user reports for this drug yet.
My bottom line
A weight loss pill that messes with your mood is a bad trade. The last one got pulled. I would stay far away until a safe dose is proven.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Monlunabant?
Monlunabant is Novo Nordisk's CB1 blocker pill, built to act mostly outside the brain. People lost 7.1 kg in 16 weeks, but anxiety, irritability and sleep problems rose with the dose. A follow-up study has to sort that out.
Monlunabant is a pill that blocks the CB1 receptor, the one cannabis acts on. It is designed to work mostly outside the brain. In a mid-stage study of 243 people, published in The Lancet Diabetes and Endocrinology, the 10 mg dose took off 7.1 kg over 16 weeks, against 0.7 kg on a dummy pill. Mood and sleep side effects rose as the dose went up. That is the same problem that got the older drug rimonabant pulled from the market. In 2025 Novo started a follow-up study to look for a dose that keeps the benefit without the harm.
How does Monlunabant work?
It blocks CB1 receptors in the body. That cuts fat storage and improves how the body handles fuel.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2024 and 2025.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 591.0 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Monlunabant, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2025Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
It took weight off, and it brought back the side effect that killed the last drug of its kind. 243 adults took monlunabant or a dummy pill for 16 weeks. The 10 mg dose removed about 7 kg against under 1 kg on the dummy. Anxiety, irritability and sleep problems rose as the dose rose. An earlier drug working the same way, rimonabant, was pulled from the market for exactly this. Whether a safe dose exists is unsettled.
7.1 kg loss at 16 weeks on 10 mg; dose-dependent neuropsychiatric effects.
- Study in people2024Novo Nordisk Phase 2a results for monlunabant
Novo Nordisk moved the drug forward to answer a safety question, not to confirm that it works. The company said the follow-up study exists to find a dose that takes weight off without the mood and sleep effects seen higher up the range. No results from that study have been reported. The company's own framing is the tell here. The open question is harm, not benefit.
Company moved to Phase 2b to define dose and safety.
Common questions
Has Monlunabant been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. Monlunabant is Novo Nordisk's CB1 blocker pill, built to act mostly outside the brain. People lost 7.1 kg in 16 weeks, but anxiety, irritability and sleep problems rose with the dose. A follow-up study has to sort that out.
What is the Monlunabant dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is Monlunabant FDA-approved?
Investigational; in mid-stage studies
Why is monlunabant a safety story?
The drug is meant to stay out of the brain. Yet anxiety, irritability and sleep problems went up with the dose in the mid-stage study. The open question is whether a lower dose keeps the weight loss without those effects.